BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38194502)

  • 1. Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature.
    Qiu L; Liu C; Li H
    Anticancer Drugs; 2024 Mar; 35(3):263-270. PubMed ID: 38194502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
    Ye Y; Zheng S
    Front Immunol; 2021; 12():785400. PubMed ID: 34880877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
    Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
    Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
    Overman M; Javle M; Davis RE; Vats P; Kumar-Sinha C; Xiao L; Mettu NB; Parra ER; Benson AB; Lopez CD; Munugalavadla V; Patel P; Tao L; Neelapu S; Maitra A
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
    Xu H; Wang X; Zhou S; Hu Q; Cao D
    Tumori; 2021 Dec; 107(6):NP24-NP27. PubMed ID: 33345750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
    Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.
    Shang L; Li P; Fan J; Zhao C; Niu X; Bian Q; Yuan Z; Kong Y; Zhu T; Xu B; Dong J; Xiang H
    Front Immunol; 2022; 13():946266. PubMed ID: 36203575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 11. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
    Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
    Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer.
    Song D; Yang X; Guo X; Sun H
    Immunotherapy; 2022 Nov; 14(16):1307-1313. PubMed ID: 36341552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report.
    Lin S; Chen W; Chen Z; Liang J; Zhong L; Jiang M
    Ann Transl Med; 2022 Mar; 10(6):380. PubMed ID: 35433988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells.
    Besaw RJ; Terra AR; Malvar GL; Chapman TR; Hertan LM; Schlechter BL
    J Natl Compr Canc Netw; 2021 Mar; 19(3):247-252. PubMed ID: 33668025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
    Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y
    Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
    Li T; Hu W; Jin L; Yin X; Kang D; Piao L
    Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
    Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
    Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
    Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
    Front Oncol; 2021; 11():628124. PubMed ID: 33791214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.